查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1863643

全球吸入式一氧化氮市场：按系统、类型、组件、应用、最终用户和地区划分－市场规模、行业趋势、机会分析和预测（2025-2033 年）

Global Inhaled Nitric Oxide Market: By System, Type, Component, Application, End Users, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 391 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

吸入式一氧化氮 (iNO) 市场正经历显着成长，预计到 2024 年将达到约 2.6617 亿美元。预测显示，到 2033 年，该市场规模将成长近一倍，达到约 4.7472 亿美元。 2025 年至 2033 年的复合年增长率 (CAGR) 为 6.64%，反映了各个医疗领域对 iNO 疗法的强劲且持续的需求。

推动市场强劲扩张的关键因素之一是对新生儿照护的日益重视。吸入式一氧化氮在治疗新生儿呼吸系统併发症方面发挥着至关重要的作用。同时，便携式吸入一氧化氮（iNO）系统的开发彻底改变了呼吸治疗，显着提高了治疗的灵活性和可及性，尤其是在患者转运和资源匮乏的环境下。这些便携式设备增强了临床医生提供及时有效护理的能力，即使在传统重症监护环境之外也是如此。

市场动态

吸入一氧化氮（iNO）市场竞争异常激烈，Mallinckrodt Pharmaceuticals、Linde plc 和 Air Liquide 等全球主要企业不断透过创新产品开发、策略联盟和扩大全球业务来争夺市场领导地位。这种竞争推动了技术和服务的进步，确保医疗保健提供者能够获得可靠且有效的 iNO 疗法。到 2024 年，这种竞争态势将体现在对产能扩张的大量投资上，以满足全球临床对吸入一氧化氮日益增长的需求。

例如，林德集团（Linde plc）在其位于荷兰的工厂新建了一座专门用于生产高纯度一氧化氮钢瓶的厂房，从而扩大了产能。此次扩建凸显了林德集团致力于维护稳健可靠的供应链的战略重点，这对于持续的患者护理至关重要。同样，液化空气集团（Air Liquide）也在美国德克萨斯州开设了一家新的生产工厂，以扩大其业务规模。

同时，总部位于波兰的普莱克斯公司（Praxair）透过建立四个独立的枢纽，优化了其包装和分销网络，这些枢纽专门用于一氧化氮钢瓶的加工和包装。这项策略性措施最大限度地减少了从大量生产到交付的停机时间，从而创造了更顺畅、更有效率的供应链。透过减少延误，普莱克斯帮助医疗机构维持充足的吸入一氧化氮库存，最终有助于改善患者的治疗效果。

核心成长驱动因子

全球致力于改善新生儿护理的努力显着推动了吸入一氧化氮 (iNO) 市场的扩张，这主要得益于人们对影响生命早期阶段的呼吸系统併发症的日益关注。人们越来越认识到解决这些疾病至关重要，因此公共卫生组织积极推广和补贴 iNO 解决方案，尤其是在资源匮乏、难以获得先进呼吸护理的地区。这些努力旨在透过提高吸入一氧化氮疗法的可及性和可负担性来消除​​新生儿护理方面的不平等现象，而吸入一氧化氮疗法对于治疗危及生命的疾病（例如新生儿持续性肺动脉高压 (PPHN)）至关重要。

新兴机会

随着便携式吸入一氧化氮 (iNO) 系统在重症监护室 (ICU) 和手术室的广泛应用，呼吸护理行业正在经历一场重大变革，取代了传统的钢瓶式设备。 此变化源自于对更灵活且方便的给药方式日益增长的需求，这些方式能够更好地适应动态变化的病患照护。在过去九个月中，北美已有超过 50 家三级医院将移动式吸入一氧化氮 (iNO) 装置纳入其治疗方案。这些便携式系统使临床医生能够更轻鬆地进行一氧化氮治疗，尤其是当患者需要在不同部门或机构间转运时，从而确保持续、不间断且有效的呼吸支持。

优化障碍

在各种医疗环境中保持吸入一氧化氮 (iNO) 剂量的一致性对于有效治疗至关重要，但设备校准的复杂性带来了巨大的挑战。根据一份行业报告显示，70 台在偏远地区运行的行动医疗设备出现了校准偏差，导致一氧化氮浓度相差数 ppm。这种偏差会影响治疗效果和病人安全，凸显了精确校准以维持预期治疗剂量的重要性。在行动医疗和资源有限的环境中，这些挑战尤其突出，因为环境因素和设备限制会进一步增加校准的复杂性。

目录

第一章：研究架构

  • 研究目标
  • 产品概述
  • 市场区隔

第二章：研究方法

  • 质性研究
    • 一手和二手资料来源
  • 量化研究
    • 一手和二手资料来源
  • 按地区划分的原始调查受访者
  • 研究假设
  • 市场规模估算
  • 资料三角验证

第三章：摘要整理：全球吸入式一氧化氮市场

第四章：全球吸入式一氧化氮市场概论

  • 产业价值链分析
    • 原料供应商
    • 製造商
    • 经销商
    • 终端用户
  • 行业展望
    • 吸入一氧化氮的临床应用
    • 吸入一氧化氮在 COVID-19 患者中的应用案例研究
    • 吸入一氧化氮治疗新生儿呼吸衰竭 (NINOS)
    • 吸入一氧化氮治疗 COVID-19 重症急性呼吸道症候群 (NOSARSCOVID)
    • 吸入一氧化氮的临床试验阶段
  • PESTLE 分析
  • 波特五力分析
    • 供应商议价能力
    • 买方协商谈判力量
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度
  • 市场动态与趋势
    • 成长推动因素
    • 阻碍因素
    • 挑战
    • 主要趋势
  • 新冠疫情对市场成长趋势的影响评估
  • 市场成长与展望
    • 2020-2033年市场收入估计与预测
    • 2020-2033年市场估计与预测（基于销售量）
    • 价格趋势分析
  • 竞争格局概览
    • 市场集中度
    • 公司市占率分析（基于价值） 2024)
    • 竞争格局分析与基准测试

第五章 全球吸入式一氧化氮市场分析：依组件划分

  • 主要发现
  • 市场规模及预测，2020-2033年
    • 硬体
    • 服务

第六章 全球吸入式一氧化氮市场分析：依系统划分

  • 主要见解
  • 市场规模及预测，2020-2033年
    • 钢瓶式系统
    • 电气系统
    • 化学式系统

第七章 全球吸入式一氧化氮市场分析：依病患群体划分类型

  • 主要发现
  • 市场规模及预测，2020-2033 年
    • 成人
    • 儿科

第八章 全球吸入一氧化氮市场分析：依应用领域划分

  • 主要见解
  • 市场规模及预测，2020-2033 年
    • 肺动脉高压
    • 结核病治疗
    • 疟疾治疗
    • 慢性阻塞性肺病 (COPD)
    • 急性呼吸窘迫症候群 (ARDS)
    • 其他

第九章 全球吸入一氧化氮市场分析：依最终使用者划分

  • 主要洞察
  • 市场规模及预测，2020-2033
    • 医院
    • 诊所
    • 门诊中心

第十章：全球吸入一氧化氮市场区域分析

  • 主要发现
  • 市场规模及预测，2020-2033
    • 北美
    • 欧洲
    • 亚太地区
    • 中东和非洲
    • 南美

第十一章：北美吸入一氧化氮市场分析

第十二章：欧洲吸入一氧化氮市场分析

第十三章：亚太地区吸入一氧化氮市场分析

第十四章：中东与非洲吸入式一氧化氮市场分析

第十五章：南美洲吸入式一氧化氮市场分析

第十六章：美国吸入式一氧化氮市场分析

第十七章：英国吸入式一氧化氮市场分析

第十八章：德国吸入式一氧化氮市场分析

第十九章：法国吸入式一氧化氮市场分析

第二十章：义大利吸入式一氧化氮市场分析

第二十一章：西班牙吸入式一氧化氮市场分析

第22章：俄罗斯吸入式一氧化氮市场分析

第23章：波兰吸入式一氧化氮市场分析

第24章：中国吸入式一氧化氮市场分析

第25章：日本吸入式一氧化氮市场分析

第26章 企业简介

  • Air Liquide Healthcare
  • Bellerophon Therapeutics
  • Beyond Air
  • Circassia Pharmaceuticals
  • Getinge
  • International Biomedical
  • LINDE
  • Mallinckrodt Pharmaceuticals
  • Praxair(NoxBox)
  • SLE
  • Vero Biotech
  • Other major players
简介目录
Product Code: AA0423426

The inhaled nitric oxide (iNO) market is experiencing substantial growth, with its valuation reaching approximately US$ 266.17 million in 2024. Projections indicate that this market will nearly double by 2033, reaching an estimated value of US$ 474.72 million. This growth corresponds to a compound annual growth rate (CAGR) of 6.64% between 2025 and 2033, reflecting strong and sustained demand for iNO therapies across various healthcare sectors.

One of the primary drivers behind the market's robust expansion is the increasing focus on neonatal care, where inhaled nitric oxide plays a critical role in treating respiratory complications in newborns. Alongside this, the development of portable iNO systems has revolutionized respiratory therapy by offering greater flexibility and accessibility, particularly during patient transfers and in resource-limited settings. These portable devices enhance the ability of clinicians to deliver timely and effective care outside traditional intensive care environments.

Noteworthy Market Developments

The inhaled nitric oxide (iNO) market is characterized by a highly competitive landscape, dominated by key global players, such as Mallinckrodt Pharmaceuticals, Linde plc, and Air Liquide. These companies continuously vie for market leadership through innovative product development, strategic partnerships, and efforts to broaden their global presence. Their competition drives advancements in technology and service, ensuring that healthcare providers have access to reliable and effective iNO therapies. In 2024, this competitive spirit is reflected in significant investments to increase production capacity, aiming to meet the growing and steady demand for inhaled nitric oxide in clinical settings worldwide.

For instance, Linde plc enhanced its production capabilities by activating a specialized wing at its facility in the Netherlands dedicated exclusively to manufacturing high-purity nitric oxide canisters. This expansion underscores Linde's strategic focus on maintaining robust and dependable supply chains, which are critical for continuous patient care. Similarly, Air Liquide has expanded its operations in the United States by commissioning a new production site in Texas.

Meanwhile, Praxair in Poland has optimized its packaging and distribution network by dedicating four separate hubs to the processing and packaging of nitric oxide cylinders. This strategic move minimizes downtime between batch production and delivery, allowing for a smoother and more efficient supply chain. By reducing delays, Praxair helps ensure that healthcare facilities can maintain adequate inventories of inhaled nitric oxide, ultimately supporting better patient outcomes.

Core Growth Drivers

Efforts to enhance neonatal care on a global scale are significantly driving the expansion of the inhaled nitric oxide (iNO) market by bringing increased attention to respiratory complications that affect the earliest stages of life. The growing recognition of the critical need to address these conditions has motivated public health organizations to actively promote and subsidize iNO solutions, especially in resource-limited areas where access to advanced respiratory therapies remains a challenge. These initiatives aim to bridge gaps in neonatal care by improving the availability and affordability of inhaled nitric oxide treatments, which are essential for managing life-threatening conditions such as persistent pulmonary hypertension of the newborn (PPHN).

Emerging Opportunity Trends

A significant transformation is underway in respiratory care with the increasing adoption of portable inhaled nitric oxide (iNO) systems, which are progressively replacing traditional cylinder-based setups in intensive care units (ICUs) and surgical theaters. This shift is driven by the growing demand for more flexible and convenient delivery methods that can better accommodate the dynamic nature of patient care. Over the past nine months, more than 50 tertiary care hospitals across North America have integrated mobile iNO units into their treatment protocols. These portable systems allow clinicians to administer nitric oxide therapy with greater ease, especially during patient transfers between departments or facilities, ensuring continuous and effective respiratory support without interruption.

Barriers to Optimization

Device calibration complexities are posing significant challenges to achieving consistent dosing of inhaled nitric oxide (iNO) across various care settings, which is crucial for effective therapeutic administration. Industry reports reveal that 70 mobile healthcare units operating in remote regions have encountered calibration discrepancies, resulting in variations in iNO concentration by several parts per million. Such fluctuations can compromise treatment efficacy and patient safety, highlighting the critical need for precise calibration to maintain the intended therapeutic dose. These challenges are particularly pronounced in mobile or resource-limited settings, where environmental factors and equipment constraints may further complicate calibration efforts.

Detailed Market Segmentation

By System, cylinder-based systems have emerged as the dominant technology in the inhaled nitric oxide market, commanding a revenue share exceeding 53.1%. This leadership position is largely due to their well-established reliability and broad compatibility with various ventilator models used in critical care settings. These systems have become the preferred choice for healthcare providers because they consistently deliver precise and controlled doses of nitric oxide, which is essential for managing severe respiratory conditions. Their robust design and ease of integration with existing respiratory equipment ensure that they remain a trusted solution in intensive care units worldwide.

By Type, in 2024, the pediatric segment of the inhaled nitric oxide market captured a dominant share of over 77.5%, due to the therapy's critical importance in treating newborns with respiratory complications. This strong market presence is largely driven by the proven efficacy of inhaled nitric oxide in managing persistent pulmonary hypertension of the newborn (PPHN) and respiratory failure, conditions that require immediate and effective intervention to prevent long-term damage or mortality. For many neonates facing hypoxic respiratory challenges, inhaled nitric oxide provides a lifesaving alternative to more invasive procedures, helping to improve oxygenation and reduce the risk of complications associated with mechanical ventilation or surgery.

By Component, Acute Respiratory Distress Syndrome (ARDS) continues to be the leading component driving the inhaled nitric oxide market, holding over 59% of the market share. The widespread use of inhaled nitric oxide for ARDS is mainly due to its proven ability to enhance oxygenation and reduce pulmonary hypertension, both of which are critical factors in managing this severe respiratory condition. ARDS patients often suffer from severe hypoxemia, a dangerously low level of oxygen in the blood, and inhaled nitric oxide serves as an effective adjunct therapy to improve their respiratory function and overall outcomes.

By End Users, hospitals remain the predominant end users in the inhaled nitric oxide market, commanding a substantial market share of over 85.59%. This dominance is clearly reflected in the heightened procurement and utilization of nitric oxide therapies across some of the world's leading medical institutions. For instance, the Mayo Clinic has reported administering more than 4,500 nitric oxide treatments within the current year, underscoring the critical role this therapy plays in managing severe respiratory and critical care cases. The widespread acceptance of inhaled nitric oxide in hospital settings highlights its importance as a lifesaving intervention for patients with complex respiratory conditions.

Segment Breakdown

  • By System
  • Cylinder-Based System
  • Electric System
  • Chemical-Based System

By Type

  • Adults
  • Pediatrics

By Components

  • Hardware
  • Mechanical Ventilator
  • Flow Sensor
  • Respiratory Circuits Connectors
  • Nitric Oxide Container
  • Nitric Oxide Analyzer
  • Inlet & Outlet Pipe
  • Digital Monitor
  • Services
  • Managed Services
  • Professional Services
  • Consulting
  • Support & Maintenance

By Applications

  • Pulmonary Hypertension
  • Tuberculosis Treatment
  • Malaria Treatment
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Acute Respiratory Distress Syndrome (ARDS)
  • Others

By End User

  • Hospitals
  • Clinics
  • Ambulatory Centers

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • Europe holds a commanding position in the inhaled nitric oxide (iNO) market, capturing 41.3% of the global market share. This dominance is largely attributed to the region's sophisticated healthcare infrastructure, well-established clinical research networks, and extensive experience in managing complex respiratory conditions. These factors collectively enable Europe to lead in the adoption and utilization of iNO therapies. The region's commitment to advancing patient care is evident through the high volume of iNO-based interventions carried out in neonatal wards.
  • Germany stands out as the leader within Europe, performing close to 4,000 neonatal iNO procedures monthly, indicating its advanced neonatal care capabilities. The United Kingdom follows, with nearly 900 specialized iNO generators deployed across National Health Service hospitals, ensuring broad access to this critical therapy. France also contributes significantly, with cardiology departments conducting around 2,500 nitric oxide-assisted procedures during the first half of 2023, highlighting the treatment's importance beyond neonatal care into cardiovascular applications.

Leading Market Participants

  • Air Liquide Healthcare
  • Bellerophon Therapeutics
  • Beyond Air
  • Circassia Pharmaceuticals
  • Getinge
  • International Biomedical
  • LINDE
  • Mallinckrodt Pharmaceuticals
  • Praxair (NoxBox)
  • SLE
  • Vero Biotech
  • Other major players

Table of Content

Chapter 1. Research Framework

  • 1.1 Research Objective
  • 1.2 Product Overview
  • 1.3 Market Segmentation

Chapter 2. Research Methodology

  • 2.1 Qualitative Research
    • 2.1.1 Primary & Secondary Sources
  • 2.2 Quantitative Research
    • 2.2.1 Primary & Secondary Sources
  • 2.3 Breakdown of Primary Research Respondents, By Region
  • 2.4 Assumption for the Study
  • 2.5 Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Inhaled Nitric Oxide Market

Chapter 4. Global Inhaled Nitric Oxide Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Raw Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Clinical Applications of Inhaled Nitric Oxide
    • 4.2.2. Case study on Use of Inhaled Nitric Oxide on COVID-19 Patients
    • 4.2.3. Inhaled Nitric Oxide Study for Respiratory Failure in Newborns (NINOS)
    • 4.2.4. Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 (NOSARSCOVID)
    • 4.2.5. Clinical Trial Phases of Inhaled Nitric Oxide
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Challenges
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2033
    • 4.7.2. Market Volume Estimates and Forecast (Units), 2020-2033
    • 4.7.3. Price Trend Analysis
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2024
    • 4.8.3. Competitor Mapping & Benchmarking

Chapter 5. Global Inhaled Nitric Oxide Market Analysis, By Component

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 5.2.1. Hardware
      • 5.2.1.1. Mechanical Ventilator
      • 5.2.1.2. Flow Sensor
      • 5.2.1.3. Respiratory Circuits Connectors
      • 5.2.1.4. Nitric Oxide Container
      • 5.2.1.5. Nitric Oxide Analyzer
      • 5.2.1.6. Inlet & Outlet Pipe
      • 5.2.1.7. Digital Monitor
    • 5.2.2. Services
      • 5.2.2.1. Managed Services
      • 5.2.2.2. Professional Services
      • 5.2.2.3. Consulting
      • 5.2.2.4. Support & Maintenance

Chapter 6. Global Inhaled Nitric Oxide Market Analysis, By System

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 6.2.1. Cylinder Based System
    • 6.2.2. Electric System
    • 6.2.3. Chemical Based System

Chapter 7. Global Inhaled Nitric Oxide Market Analysis, By Patient Type

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 7.2.1. Adults
    • 7.2.2. Pediatrics

Chapter 8. Global Inhaled Nitric Oxide Market Analysis, By Application

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 8.2.1. Pulmonary Hypertension
    • 8.2.2. Tuberculosis Treatment
    • 8.2.3. Malaria Treatment
    • 8.2.4. Chronic Obstructive Pulmonary Applications (COPD)
    • 8.2.5. Acute Respiratory Distress Syndrome (ARDS)
    • 8.2.6. Others

Chapter 9. Global Inhaled Nitric Oxide Market Analysis, By End User

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 9.2.1. Hospitals
    • 9.2.2. Clinics
    • 9.2.3. Ambulatory Centers

Chapter 10. Global Inhaled Nitric Oxide Market Analysis, By Region

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 10.2.1. North America
      • 10.2.1.1. The U.S.
      • 10.2.1.2. Canada
      • 10.2.1.3. Mexico
    • 10.2.2. Europe
      • 10.2.2.1. Western Europe
        • 10.2.2.1.1. The UK
        • 10.2.2.1.2. Germany
        • 10.2.2.1.3. France
        • 10.2.2.1.4. Italy
        • 10.2.2.1.5. Spain
        • 10.2.2.1.6. Rest of Western Europe
      • 10.2.2.2. Eastern Europe
        • 10.2.2.2.1. Poland
        • 10.2.2.2.2. Russia
        • 10.2.2.2.3. Rest of Eastern Europe
    • 10.2.3. Asia Pacific
      • 10.2.3.1. China
      • 10.2.3.2. India
      • 10.2.3.3. Japan
      • 10.2.3.4. South Korea
      • 10.2.3.5. Australia & New Zealand
      • 10.2.3.6. ASEAN
      • 10.2.3.7. Rest of Asia Pacific
    • 10.2.4. Middle East & Africa
      • 10.2.4.1. UAE
      • 10.2.4.2. Saudi Arabia
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of MEA
    • 10.2.5. South America
      • 10.2.5.1. Argentina
      • 10.2.5.2. Brazil
      • 10.2.5.3. Rest of South America

Chapter 11. North America Inhaled Nitric Oxide Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 11.2.1. By Component
    • 11.2.2. By System
    • 11.2.3. By Patient Type
    • 11.2.4. By Application
    • 11.2.5. By End User
    • 11.2.6. By Country

Chapter 12. Europe Inhaled Nitric Oxide Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 12.2.1. By Component
    • 12.2.2. By System
    • 12.2.3. By Patient Type
    • 12.2.4. By Application
    • 12.2.5. By End User
    • 12.2.6. By Country

Chapter 13. Asia Pacific Inhaled Nitric Oxide Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 13.2.1. By Component
    • 13.2.2. By System
    • 13.2.3. By Patient Type
    • 13.2.4. By Application
    • 13.2.5. By End User
    • 13.2.6. By Country

Chapter 14. Middle East & Africa Inhaled Nitric Oxide Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 14.2.1. By Component
    • 14.2.2. By System
    • 14.2.3. By Patient Type
    • 14.2.4. By Application
    • 14.2.5. By End User
    • 14.2.6. By Country

Chapter 15. South America Inhaled Nitric Oxide Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 15.2.1. By Component
    • 15.2.2. By System
    • 15.2.3. By Patient Type
    • 15.2.4. By Application
    • 15.2.5. By End User
    • 15.2.6. By Country

Chapter 16. US Inhaled Nitric Oxide Market Analysis

  • 16.1. Key Insights
  • 16.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 16.2.1. By Component
    • 16.2.2. By System
    • 16.2.3. By Patient Type
    • 16.2.4. By Application
    • 16.2.5. By End User

Chapter 17. UK Inhaled Nitric Oxide Market Analysis

  • 17.1. Key Insights
  • 17.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 17.2.1. By Component
    • 17.2.2. By System
    • 17.2.3. By Patient Type
    • 17.2.4. By Application
    • 17.2.5. By End User

Chapter 18. Germany Inhaled Nitric Oxide Market Analysis

  • 18.1. Key Insights
  • 18.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 18.2.1. By Component
    • 18.2.2. By System
    • 18.2.3. By Patient Type
    • 18.2.4. By Application
    • 18.2.5. By End User

Chapter 19. France Inhaled Nitric Oxide Market Analysis

  • 19.1. Key Insights
  • 19.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 19.2.1. By Component
    • 19.2.2. By System
    • 19.2.3. By Patient Type
    • 19.2.4. By Application
    • 19.2.5. By End User

Chapter 20. Italy Inhaled Nitric Oxide Market Analysis

  • 20.1. Key Insights
  • 20.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 20.2.1. By Component
    • 20.2.2. By System
    • 20.2.3. By Patient Type
    • 20.2.4. By Application
    • 20.2.5. By End User

Chapter 21. Spain Inhaled Nitric Oxide Market Analysis

  • 21.1. Key Insights
  • 21.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 21.2.1. By Component
    • 21.2.2. By System
    • 21.2.3. By Patient Type
    • 21.2.4. By Application
    • 21.2.5. By End User

Chapter 22. Russia Inhaled Nitric Oxide Market Analysis

  • 22.1. Key Insights
  • 22.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 22.2.1. By Component
    • 22.2.2. By System
    • 22.2.3. By Patient Type
    • 22.2.4. By Application
    • 22.2.5. By End User

Chapter 23. Poland Inhaled Nitric Oxide Market Analysis

  • 23.1. Key Insights
  • 23.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 23.2.1. By Component
    • 23.2.2. By System
    • 23.2.3. By Patient Type
    • 23.2.4. By Application
    • 23.2.5. By End User

Chapter 24. China Inhaled Nitric Oxide Market Analysis

  • 24.1. Key Insights
  • 24.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 24.2.1. By Component
    • 24.2.2. By System
    • 24.2.3. By Patient Type
    • 24.2.4. By Application
    • 24.2.5. By End User

Chapter 25. Japan Inhaled Nitric Oxide Market Analysis

  • 25.1. Key Insights
  • 25.2. Market Size and Forecast, 2020-2033 (US$ Mn & Units)
    • 25.2.1. By Component
    • 25.2.2. By System
    • 25.2.3. By Patient Type
    • 25.2.4. By Application
    • 25.2.5. By End User

Chapter 26. Company Profile (Company Overview, Financial Matrix, Key Type landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 26.1. Air Liquide Healthcare
  • 26.2. Bellerophon Therapeutics
  • 26.3. Beyond Air
  • 26.4. Circassia Pharmaceuticals
  • 26.5. Getinge
  • 26.6. International Biomedical
  • 26.7. LINDE
  • 26.8. Mallinckrodt Pharmaceuticals
  • 26.9. Praxair (NoxBox)
  • 26.10. SLE
  • 26.11. Vero Biotech
  • 26.12. Other major players